潜在的PDE4B抑制剂作为对抗SARS-CoV-2感染的有希望的候选者
Federica Giuzio1,2, Maria Grazia Bonomo2, Alessia Catalano3
1International PhD Programme 'Sciences', Department of Science, University of Basilicata, Viale dell'Ateneo Lucano n.10, 85100 Potenza, Italy.
Biomolecular concepts
|November 1, 2023
概括
研究人员探索了用于治疗COVID-19的新型化酶4B (PDE4B) 抑制剂,其目标是具有比现有的PDE4抑制剂更少副作用的抗炎和支气管扩展作用.
科学领域:
- 药理学 药理学是指药理学的学科.
- 病毒学 病毒学
- 药用化学 医学化学
背景情况:
- 严重急性呼吸道综合征冠状病毒-2 (SARS-CoV-2) 导致COVID-19,主要影响肺系统,类似于COPD.
- 固酶4 (PDE4) 抑制剂通过增加cAMP水平提供抗炎和支气管扩展作用.
- 像皮克拉米拉斯特这样的现有的PDE4抑制剂具有剂量限制的副作用 (恶心,吐).
研究的目的:
- 调查选择性化酶4B (PDE4B) 抑制作为对抗SARS-CoV-2的战略.
- 为了确定潜在的药物候选者,减少COVID-19治疗的副作用.
主要方法:
- 对21种针对PDE4B催化部位的内部化合物进行了分子对接研究.
- 化合物与PDE4B活性部位对接,将它们的位置与已知的抑制剂皮克拉米拉斯特进行比较.
- 对所研究的化合物进行了药物相似性预测研究.
主要成果:
- 21种内部化合物被对接到PDE4B催化部位.
- 大多数化合物与皮克拉米拉斯特显著叠加,表明潜在的结合亲和力.
- 对选化合物的药物相似性进行了评估.
结论:
- 选择性PDE4B抑制是开发新型COVID-19治疗方法的一个有希望的策略.
- 研究的化合物显示出作为选择性PDE4B抑制剂的潜力,具有改善的副作用概况.
- 对这些化合物的进一步调查可能会导致对COVID-19的有效治疗方法.
相关概念视频
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
163
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
163
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
190
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
190